Abstract Background Anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements have been reported in 2-13% of patients with non-small cell lung cancer (NSCLC). Patients with ALK rearrangements do not respond to EGFR-specific tyrosine kinase inhibitors (TKIs); however, they do benefit from small molecule inhibitors targeting ALK. Results In this study, fluorescence in situ hybridization (FISH) using a break-apart probe for the ALK gene was performed on formalin fixed paraffin-embedded tissue to determine the incidence of ALK rearrangements and hybridization patterns in a large unselected cohort of 1387 patients with a referred diagnosis of non-small cell lung cancer (1011 of these patients had a histologic diagnosis of adenocarci...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
IntroductionBreak-apart fluorescence in situ hybridization (FISH) is the FDA-approved assay for dete...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...
IntroductionPatients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (A...
INTRODUCTION ALK gene rearrangements occur in ~5% of lung adenocarcinomas (ACA), leading to ALK ove...
Objectives: Targeted therapies in the management of patients with lung cancer provide significantly ...
Patients and methods Testing for Anaplastic Lymphoma Kinas (ALK) rearrangement is now recommended fo...
Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NS...
Anaplastic lymphoma kinase (ALK) gene can be oncogenic either by forming fusion with other genes, am...
IntroductionAnaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patients...
Introduction:Translocation of the anaplastic lymphoma kinase (ALK) gene is involved in the tumorigen...
Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patien...
EML4-ALK is a new driver gene of non-small cell lung cancer and a target of crizotinib. The objectiv...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
IntroductionBreak-apart fluorescence in situ hybridization (FISH) is the FDA-approved assay for dete...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...
IntroductionPatients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (A...
INTRODUCTION ALK gene rearrangements occur in ~5% of lung adenocarcinomas (ACA), leading to ALK ove...
Objectives: Targeted therapies in the management of patients with lung cancer provide significantly ...
Patients and methods Testing for Anaplastic Lymphoma Kinas (ALK) rearrangement is now recommended fo...
Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NS...
Anaplastic lymphoma kinase (ALK) gene can be oncogenic either by forming fusion with other genes, am...
IntroductionAnaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patients...
Introduction:Translocation of the anaplastic lymphoma kinase (ALK) gene is involved in the tumorigen...
Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patien...
EML4-ALK is a new driver gene of non-small cell lung cancer and a target of crizotinib. The objectiv...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...